TNXP
Tonix Pharmaceuticals Holding Corp
10.20$
-3.3%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 98.7% | 98.6% | 98.7% | 98.8% | 99.0% | 95.8% | 89.6% | 78.5% | 57.9% | 30.9% | 73.1% | 82.6% | |
| 96.6% | 40.8% | 68.9% | 95.3% | 95.1% | 77.3% | 78.5% | 74.2% | 53.3% | 16.2% | 60.6% | 74.9% | |
| 96.6% | 91.5% | 95.0% | 95.3% | 95.1% | 77.3% | 78.5% | 74.2% | 53.3% | 16.2% | 60.6% | 74.9% | |
| 1.3% | 6.0% | 1.4% | 1.8% | 2.0% | 6.9% | 7.8% | 3.2% | 3.6% | 3.0% | 4.9% | 3.5% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | -6.9% | -7.8% | – | -3.6% | 9.2% | 5.2% | 2.2% | |
| 0.8% | 0.7% | 0.5% | 0.3% | 0.2% | 0.2% | 10.0% | – | 41.9% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | 0.0% | 0.6% | 0.0% | – | |
| 0.0% | 0.3% | 0.4% | 0.4% | 0.5% | 0.8% | 0.1% | 0.0% | 0.1% | 6.3% | 0.1% | 0.0% | |
| 8.7% | 14.4% | 7.8% | 8.0% | 10.1% | 35.3% | 10.7% | 9.2% | 8.2% | 31.7% | 14.3% | 11.6% | |
| 8.6% | 14.1% | 7.7% | 7.9% | 10.1% | 35.3% | 10.0% | 9.0% | 8.1% | 12.2% | 11.2% | 11.1% | |
| – | – | – | – | – | 2.4% | 0.6% | 0.2% | 0.2% | 1.7% | 0.2% | 0.0% | |
| 3.8% | 6.5% | 3.2% | 4.8% | 5.3% | 21.1% | 4.7% | 5.5% | 3.6% | 2.4% | 2.8% | 2.9% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | 4.2% | 2.9% | – | |
| 91.3% | 85.6% | 92.2% | 92.0% | 89.9% | 64.7% | 89.3% | 90.8% | 91.8% | 68.3% | 85.7% | 88.4% | |
| -137.4% | -217.8% | -513.4% | -606.9% | -716.0% | -1,491.1% | -272.5% | -149.4% | -208.3% | -388.9% | -448.6% | -308.4% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.5% | 3.1% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.